Yisaipu
ApprovedSmall molecule
Yisaipu is one of 48 small molecule programs targeting Arthritis. It is currently in Approved.
2
Indications
4
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPhase 3
Taltz
Eli LillyPhase 3
Aleve
Alnylam PharmaceuticalsPhase 3
Stelara
Johnson & JohnsonPhase 3
Bimzelx
UCBPhase 3
Remicade
OOrganon and Co
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
SHR0302
RReistone Biopharma Company Limited
Phase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
Yisaipu
SSun Yat-sen University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pterygium1 trial
Arthritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yisaipu. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSun Yat-sen University